Summary

No conclusions possible: low‐ to very low‐quality evidence, or insufficient evidence to comment on the effectiveness, more evidence needed Moderate‐quality evidence suggested increased total costs per 100 women of approximately AUD 33,000 associated with the treatment and of approximately AUD 6000 associated costs for the families of women with GDM who were treated with lifestyle intervention compared to usual care or diet alone (Table 12). This was mainly due to increased surveillance and increased contact with health professionals. The table was reprinted with permission from Brown 2017b. Although these data were assessed as being 'moderate‐quality', since it was based on narrative data, it could not be classified as 'promising'. Very low‐quality evidence suggested decreased costs for telemedicine versus standard care and self‐versus periodic‐monitoring. Very low‐quality evidence suggested increased costs for insulin versus oral antidiabetic pharmacological therapy